Special Issues

Special Issue Title: Contemporary management of Heart Failure in association with renal outcomes and prognosis

· Print Special Issue Flyer

· Deadline for manuscript submissions:  30 September 2021

Special Issue Editor

Guest Editor

        Dr. Emmanuel Androulakis

        Royal Brompton & Harefield Hospital NHS Foundation Trust, London, UK

Website | E-Mail

Interests: Multimodality Cardiovascular Imaging, Cardiac Magnetic Resonance, Inherited Cardiac Conditions, Hypertension, Heart Failure

        Dr. Eirini Lioudaki

        King’s College Hospital, London, UK

Website | E-Mail

Interests: Cardiovascular conditions in renal disease, Cardio-renal syndrome, Renal transplant

Special Issue Information

Dear Colleagues,

Heart failure and, more so, the interplay with kidney disease, have been a challenging scientific conundrum in terms of management and outcomes for the last few decades. the definition of cardiorenal syndrome (CRS) includes a spectrum of disorders involving both the heart and kidneys in which acute or chronic dysfunction in one organ may lead to acute or chronic dysfunction in the other, and despite numerous attempts to clearly define the different phenotypes, most commonly there is a significant overlap. Despite several advances over the years in the management of the two interrelated conditions, there are several remaining unmet targets and needs.

Most recently, the evolving field of heart failure management has been excitingly expanding with the introduction of new pharmacological and interventional management approaches. Pharmacological agents such as sodium-glucose co-transporter-2 (SGLT2) have been introduced and and its use is now well-established in clinical practice. Over the last months, the advent of a new pharmacological class has been warmly welcomed by the international cardiology scientific community. With primary indication another major disease, type 2 diabetes, SGLT2 inhibitors, were unexpecteldy shown to exert remarkable cardiovascular benefits, more so in association with heart failure morbidity and mortality. Most interestingly, these beneficial effects were independent of diabetes status or a glucose lowering effect but present in non-diabetic individuals, with mediating mechanisms still requiring further clarification. The same agents on the other hand, appear to exert equally impressive positive effects with regards to the progression of renal disease, which are again independent of their antidiabetic actions. This long-awaited landmark in the combined management of heart and renal disease, further highlights the underlying interrelation and the need for a unified approach to improve outcomes.

Dr. Emmanuel Androulakis and Dr. Eirini Lioudaki

Guest Editors


Manuscript Submission Information

Manuscripts should be submitted online at https://rcm.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reviews in Cardiovascular Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1950. Submitted papers should be well formatted and use good English.


Heart failure with reduced ejection fraction; Heart failure with preserved ejection fraction; Acute heart failure; Chronic kidney disease; Acute kidney injury; Sodium-glucose co-transporter-2; Pharmacological treatment; Ultrafiltration

Share This Special Issue


Planned Papers

Title: Role of peritoneal dialysis in refractory heart failure
Authors: Ronald Morales, Francesc Barbosa and Núria Farré

Title: RoCardioprotective Effects of Ibutamoren Mesylate (MK-677) in Diabetic Patients with Heart Failure: The Translational Biology of Ghrelin and Growth Hormone Metabolim
Authors: Mouhamed Nashawi, Mahmoud S. Ahmed, Mujahed Abualfoul, Osama Issa and Robert Chilton

Please wait a minute...
For Selected: Toggle Thumbnails
Peritoneal dialysis in heart failure: focus on kidney and ventricular dysfunction
Ronald O. Morales, Francesc Barbosa, Nuria Farre
Reviews in Cardiovascular Medicine    2021, 22 (3): 649-657.   DOI: 10.31083/j.rcm2203075
Abstract185)   HTML28)    PDF(pc) (133KB)(271)       Save
Heart failure is a significant health problem worldwide. Despite all the new therapies available nowadays, many patients will reach advanced stages of the disease. Diuretic resistance, kidney dysfunction, and refractory congestion, all highly prevalent in advanced heart failure, frequently complicate the situation, making it more challenging to manage. Ultrafiltration through hemodialysis or peritoneal dialysis can be alternative options to treat fluid overload. Peritoneal dialysis has gained increased interest in the last decades due to several benefits such as functional class improvement, reduction in hospital admissions, improvement in quality of life, and even a reduction in mortality shown by numerous cohort studies. However, the majority of the studies were observational and with a limited number of patients. In addition, the optimal timing for the initiation of this type of therapy and the subgroup of patients who would benefit the most from it is unknown. Hence, randomized controlled trials in this subject are urgently needed. We aim to review the contemporary evidence of peritoneal dialysis in patients with heart failure and diuretic resistance across the spectrum of ventricular dysfunction and degree of renal dysfunction.
Related Articles | Metrics

Current Issue

  • Volume 22, Issue 3